Cabergoline monotherapy in the long-term treatment of Cushing's disease.
about
Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease ParadigmsClinical use of pasireotide for Cushing's disease in adultsUpdate in the medical therapy of Cushing's diseaseThe Treatment of Cushing's Disease.Role of "old" pharmacological agents in the treatment of Cushing's syndromeCushing's disease: a multidisciplinary overview of the clinical features, diagnosis, and treatmentPasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.Update on medical treatment for Cushing's disease.Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasiaHigh variability in baseline urinary free cortisol values in patients with Cushing's disease.Cushing's syndrome: epidemiology and developments in disease management.Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelinePasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trialManagement Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to EctopicsMedical management of Cushing's disease: what is the future?Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline.The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study.Quality of life and other outcomes in children treated for Cushing syndrome.New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapyCharacterization of persistent and recurrent Cushing's diseaseRecent advances in the medical treatment of Cushing's disease.Management of Cushing disease.Mifepristone: is there a place in the treatment of Cushing's disease?Recent developments in drug therapy for Cushing's disease.Efficacy of medical treatment in Cushing's disease: a systematic review.Medical management of Cushing's disease.Managing Cushing's disease: the state of the art.Bilateral adrenalectomy for Cushing's disease.New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.Pituitary-directed medical therapy in Cushing's disease.Medical combination therapies in Cushing's disease.Emerging drugs for Cushing's disease.Cushing's syndrome: an update on current pharmacotherapy and future directions.USP8: a novel therapeutic target for Cushing's disease.Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.Diabetes in Cushing Disease.Recent Progress in the Medical Therapy of Pituitary TumorsRemission with cabergoline in adolescent boys with Cushing's disease.Treatment patterns in Cushing's disease patients in two large United States nationwide databases: application of a novel, graphical methodology.AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.
P2860
Q26741707-AEE5A5AE-4D1C-4DAF-B589-0D1617CC948DQ26858933-1DF69BDF-BC5E-4BAC-9E23-61511B73D7EEQ26865203-D35A4363-51BA-40D3-8B1F-1280F2AE7E72Q27010590-0B454F06-751A-4FB6-9BB8-F62A265C9CBCQ28067685-C23937CE-1ADB-4341-92D9-E18663824AC9Q28071635-151B3AFB-A1EE-4053-A538-7E001C59C1EBQ33163578-66A1B421-B8BF-47EB-843D-4B663E171D27Q33802284-B116969F-99C0-4361-96FC-575DE0F279AEQ34431162-9B278153-87AC-4BF1-A066-B24E96493DC7Q34507215-77F93FEE-8568-4A82-ABE5-C4DD92CF32C2Q35531889-9189439C-B1A3-4135-85FA-66BE8B83B8FBQ35916555-094D839D-BE6C-4953-AC14-E3BF8FA895D6Q36030010-6557A444-3954-448B-9DBD-4F6C8E099D27Q36184067-F174AD94-18C3-4C16-B66E-19E799EE2974Q36236884-0D403019-AB19-4C4D-997E-38C991B63657Q36471795-A80DFF14-5639-46B6-A64C-5666A3AE7AC7Q36681083-FB9FF5C1-0431-4E16-AA46-8C6950A4C017Q36981968-6D756B6D-475F-4BA7-83D3-EEFD60913450Q37049132-EA354236-9D1A-48DB-ACE0-0C524953E737Q37610803-DE876E39-AAF8-4C80-AB54-20845A0D6A0AQ37621524-079F3E4F-2E7B-4145-88A9-0FC08EAA97D2Q37837501-5AAB7186-C91D-4CE0-A293-6AB28FE3474BQ38063404-AD950215-3A91-4A5E-AC07-C79B71C29E00Q38112082-A4575D58-69E1-4797-BB57-5FA1B7E6BB28Q38151882-A6804F51-0558-4071-AFB1-F3C1EEF1AE38Q38154515-C7387586-C427-4089-892D-AE4E910BFF31Q38177740-C1AACE01-EB93-4558-BE0F-0F15D6E42AB5Q38310473-30383944-DB84-4724-A185-BFA39D142A6EQ38328843-7A88C7C1-35BA-4B22-B495-14CA7544D90FQ38334659-2AA0D830-3579-482E-A421-5E1B752669B5Q38342520-D9D7ED5D-41E0-4E7C-874C-D5177D6328D6Q38505947-1F7C60FF-58A8-417E-A17C-0043800182D2Q38541695-26C9CC86-7951-4B4F-A10A-068F75B982C3Q38545050-835E2909-8CEA-4C60-BA9B-AF6FD54C93F8Q38718807-DEFF0B4A-A20C-4066-BFFA-B3F90DAF08CEQ39212408-878EB1FA-0451-46DF-BD16-D6B93328C209Q39420116-B808DC5D-1D93-4856-B0B1-9B18AA6653CEQ42925500-69281C21-10BA-4330-B112-7CACAE4A6426Q43656346-32B4E76A-711C-4275-B7BE-068676FC57EAQ50524034-4B429721-2DCC-4682-81F9-7422A0953DA3
P2860
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@en
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@nl
type
label
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@en
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@nl
prefLabel
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@en
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@nl
P2093
P356
P1476
Cabergoline monotherapy in the long-term treatment of Cushing's disease.
@en
P2093
André Lacroix
Ariane Godbout
Hugues Beauregard
Karina Danilowicz
Marcos Manavela
Oscar Domingo Bruno
P304
P356
10.1530/EJE-10-0382
P577
2010-08-11T00:00:00Z